JOINT (JYNT) Company Report

The Joint Corp. reported Q4 2025 revenue from continuing operations increased 3.1% to $15.2 million, and consolidated adjusted EBITDA increased 7.8% to $3.6 million. However, system-wide sales were down 3.9% to $130 million, and comp sales decreased 3.8%. For the full year 2025, system-wide sales were flat at $532 million, and consolidated adjusted EBITDA rose 13.9% to $13 million.
The company is on track to complete its Joint 2.0 transformation by the end of 2026, aiming to become a pure-play franchisor. Significant progress has been made in refranchising efforts, with 48 corporate-owned clinics remaining (down from 135 at the start of the process) and agreements in place for the sale of 27 clinics.
To address declining new patient counts, The Joint has shifted its marketing message to pain relief, increased national advertising, and improved SEO for AI-driven search environments. The company is also piloting price increases across approximately 300 clinics, with $10 increases showing more benefit.
For full year 2026, the company expects system-wide sales to range from $519 million to $552 million, comp sales between -3% and 3%, and consolidated adjusted EBITDA from $12.5 million to $13.5 million. As a pure-play franchisor, the company targets an adjusted EBITDA margin of 19%-21% and a net income margin of 13%-15%.

30 minutes ago

Transcript

The Joint Corp. Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance, and Progresses Towards Pure-Play Franchisor Model

JYNT

Earnings

Guidance Update

Share Buyback

The Joint Corp. reported Q4 2025 revenue from continuing operations increased 3.1% to $15.2 million and consolidated adjusted EBITDA increased 7.8% to $3.6 million. For the full year 2025, revenue was $54.9 million and consolidated adjusted EBITDA rose 13.9% to $13 million.
The company provided 2026 guidance, projecting system-wide sales between $519 million and $552 million, comp sales in the range of -3% to 3%, and consolidated adjusted EBITDA between $12.5 million and $13.5 million.
The Joint Corp. is on track to complete its Joint 2.0 transformation by the end of 2026, aiming to become a pure-play franchisor with 48 corporate-owned clinics remaining. This transition is expected to result in a pure-play franchisor adjusted EBITDA margin of 19%-21% and a net income margin of 13%-15%.
In Q4 2025, the company repurchased 1.1 million shares for $9 million, contributing to a total of 1.3 million shares repurchased for $11.3 million in 2025.

1 hour ago

Transcript

The Joint Corp. Reports Q4 2025 Results and Progress Towards Pure-Play Franchisor Model

JYNT

Earnings

Guidance Update

Accounting Changes

The Joint Corp. reported Q4 2025 consolidated Adjusted EBITDA of $3.6 million, an increase of 7.8% compared to Q4 2024, despite a 3.9% decrease in system-wide sales to $140 million and a 3.8% decline in comparable sales for the same period.
The company is progressing towards becoming a pure-play franchisor, having refranchised 27 company-owned or managed clinics since the beginning of 2025, with 48 clinics remaining company-owned or managed.
Management reiterated its 2026 guidance for system-wide sales, comparable sales, consolidated Adjusted EBITDA, and new franchised clinic openings.
New accounting adjustments will consolidate the full operations of professional corporations (PCs), which will increase revenue and general and administrative expenses by an identical amount, with no impact on the bottom line except for deferred revenue recognition from treatment packages and wellness plans.

1 hour ago

Presentation

The Joint Corp. Reports Q4 and Full Year 2025 Financial Results

JYNT

Earnings

Guidance Update

Share Buyback

The Joint Corp. reported Q4 2025 revenues of $15.2 million, an increase of 3.1% year over year, and full year 2025 revenues of $54.9 million.
Consolidated net income significantly improved to $1.0 million in Q4 2025 (compared to $18,000 in Q4 2024) and reached $2.9 million for the full year 2025 (compared to a net loss of $5.8 million in 2024).
Consolidated Adjusted EBITDA increased 7.8% to $3.6 million in Q4 2025 and 13.9% to $13.0 million for the full year 2025.
The company repurchased 1.1 million shares for $9.0 million in Q4 2025, contributing to a total of 1.3 million shares for $11.3 million repurchased in 2025.
For 2026, The Joint Corp. provided guidance expecting system-wide sales between $519 million and $552 million and Consolidated Adjusted EBITDA between $12.5 million and $13.5 million.

3 hours ago

8-K

The Joint Corp. Sells 22 Clinics and Terminates Agreement for 45 California Clinics

JYNT

M&A

New Projects/Investments

The Joint Corp. signed an Asset Purchase Agreement (APA) for the sale of 22 corporate-owned or managed clinics to three buying groups for $1.5 million.
These clinics are located in Virginia, North Carolina, South Carolina, and Georgia, with buyers expected to assume operations in mid-December 2025.
The company also delivered a notice to terminate the APA for 45 clinics in Southern California, an agreement that was originally signed on November 2, 2025.

Dec 11, 2025, 9:52 PM

Press Release

JYNT Announces Q3 2025 Financial Results and Revised 2025 Guidance

JYNT

Earnings

Guidance Update

Share Buyback

JYNT reported a 36% increase in Q3 2025 consolidated Adjusted EBITDA over Q3 2024, reaching $3.3 million. However, Q3 2025 system-wide sales decreased by (1.5)% and comparable sales decreased by (2.0)%.
The company revised its 2025 guidance, with current projections for system-wide sales between $530 million and $534 million, comparable sales between (1)% and 0%, and new franchised clinic openings between 30 and 35.
JYNT is focused on becoming a pure-play franchisor, with 92% of its portfolio franchised and potential buyers identified for remaining corporate clinics.
The balance sheet remains strong with $29.7 million in unrestricted cash and no debt as of September 30, 2025. The company also purchased 540,000 shares for $5 million and authorized up to another $12 million for stock repurchases.
JYNT implemented new accounting adjustments to consolidate the full operations of professional corporations (PCs), which will increase revenue and G&A expenses by an identical amount, with no impact on the bottom line except for deferred revenue from treatment packages and wellness plans.

Nov 6, 2025, 10:00 PM

Presentation

JYNT Reports Q3 2025 Results, Updates Guidance, and Advances Refranchising Efforts

JYNT

Earnings

Guidance Update

Share Buyback

The Joint Corporation reported Q3 2025 revenue from continuing operations increased 6% to $13.4 million and consolidated adjusted EBITDA grew 36% to $3.3 million, despite system-wide sales decreasing 1.5% to $127 million and comp sales declining 2% compared to Q3 2024.
The company is progressing towards becoming a pure-play franchisor, with an initial agreement to sell 45 corporate clinics for $4.5 million and ongoing negotiations for 33 additional clinics.
Strategic initiatives include a new national marketing campaign focused on pain relief, funded by a reallocation of franchisee ad spend, and a three-tiered pricing pilot for wellness plans launched in November.
JYNT revised its full-year 2025 guidance, projecting system-wide sales between $530-$534 million and comp sales in the range of -1% to flat, while maintaining consolidated adjusted EBITDA guidance of $10.8-$11.8 million.
Liquidity remains strong with $29.7 million in unrestricted cash as of September 30, 2025, and the board authorized an additional $12 million for stock repurchases following $5 million in buybacks during and after Q3 2025.

Nov 6, 2025, 10:00 PM

Transcript

The Joint Corp. Reports Q3 2025 Financial Results and Updates Guidance

JYNT

Earnings

Share Buyback

Guidance Update

The Joint Corp. reported Q3 2025 revenue of $13.4 million, a 6% increase compared to Q3 2024, with consolidated net income of $855,000 (compared to a net loss of $3.2 million in Q3 2024) and Adjusted EBITDA for consolidated operations increasing 36% to $3.3 million.
The company's Board of Directors authorized an additional $12 million for its stock repurchase program, extending the authorization through November 4, 2027, after repurchasing 540,000 shares for $5 million between August and October.
System-wide sales for Q3 2025 declined 1.5% to $127.3 million, and comp sales were (2.0)%.
The 2025 guidance for system-wide sales was revised to a range of $530 million to $534 million and comp sales to (1)% to 0%, while consolidated Adjusted EBITDA guidance remained at $10.8 million to $11.8 million.

Nov 6, 2025, 9:09 PM

8-K

The Joint Corp. Authorizes Additional $12 Million for Stock Repurchase Program

JYNT

Share Buyback

The Joint Corp. board of directors has authorized an additional $12 million for its stock repurchase program.
This authorization follows the completion of an initial $5 million tranche, which resulted in the buyback of 540,000 shares between August and October.
CEO Sanjiv Razdan stated that this action reinforces the company's commitment to disciplined capital allocation and its belief that the current share price does not fully recognize its long-term valuation.

Nov 5, 2025, 12:05 PM

Press Release